BL-M07D1, an antibody- drug conjugate directed to HER2 in patients with locally advanced or metastatic Breast Cancer with HER2-positive/low-expression and other solid tumors: Results from a first-in-human phase 1 study

被引：0
|
作者：
Song, Erwei
Yao, Herui
Sun, Meili
Zong, Hong
Lin, Rongbo
Zou, Wen
Ding, Muran
Yu, Jing
Xiao, Sa
Wang, Hongwei
Zhu, Hai
Olivo, Martin
Zhu, Yi
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-04-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-04-03
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Updated findings of a first-in-human, phase I study of margetuximab (M), an Fc-optimized chimeric monoclonal antibody (MAb), in patients (pts) with HER2-positive advanced solid tumors.
    Burris, Howard A.
    Giaccone, Giuseppe
    Im, Seock-Ah
    Bauer, Todd Michael
    Oh, Do-Youn
    Jones, Suzanne Fields
    Nordstrom, Jeffrey L.
    Li, Hua
    Carlin, David A.
    Baughman, Jan E.
    Lechleider, Robert Joseph
    Bang, Yung-Jue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [42] Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer
    Kaufman, Peter A.
    Wildiers, Hans
    Freyer, Gilles
    Kemeny, Margaret
    Goncalves, Anthony
    Jerusalem, Guy
    Stopeck, Alison
    Vrindavanam, Nandagopal
    Dalenc, Florence
    Nanayakkara, Nuwan
    Wu, Benjamin
    Pickett, Cheryl A.
    CLINICAL BREAST CANCER, 2019, 19 (01) : 47 - 57
  • [43] Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
    Pamela Munster
    Ian E. Krop
    Patricia LoRusso
    Cynthia Ma
    Barry A. Siegel
    Anthony F. Shields
    István Molnár
    Thomas J. Wickham
    Joseph Reynolds
    Karen Campbell
    Bart S. Hendriks
    Bambang S. Adiwijaya
    Elena Geretti
    Victor Moyo
    Kathy D. Miller
    British Journal of Cancer, 2018, 119 : 1086 - 1093
  • [44] First-in-human phase 1/2 study of MCLA-128, a full length IgG1 bispecific antibody targeting HER2 and HER3: Final phase 1 data and preliminary activity in HER2+metastatic breast cancer (MBC).
    Alsina, Maria
    Boni, Valentina
    Schellens, Jan H. M.
    Moreno, Victor
    Bol, Kees
    Westendorp, Martine
    Sirulnik, L. Andres
    Tabernero, Josep
    Calvo, Emiliano
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] A phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+breast cancer (BC)
    Beeram, M.
    Burris, H. A., III
    Modi, S.
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Holden, S. N.
    Lutzker, S. G.
    Krop, I. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] A Phase Ib/II Trial of Trastuzumab-DM1 with Pertuzumab for Patients with HER2-Positive, Locally Advanced or Metastatic Breast Cancer: Interim Efficacy and Safety Results
    Dieras, V.
    Harbeck, N.
    Albain, K.
    Burris, H.
    Awada, A.
    Crivellari, D.
    Andre, F.
    Choi, Y. J.
    Huang, J.
    Miller, K. D.
    CANCER RESEARCH, 2010, 70
  • [47] Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
    Martin, M.
    Fumoleau, P.
    Dewar, J. A.
    Albanell, J.
    Limentani, S. A.
    Campone, M.
    Chang, J. C.
    Patre, M.
    Strasak, A.
    de Haas, S. L.
    Xu, J.
    Garcia-Saenz, J. A.
    ANNALS OF ONCOLOGY, 2016, 27 (07) : 1249 - 1256
  • [48] A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)
    Beeram, M.
    Krop, I.
    Modi, S.
    Tolcher, A.
    Rabbee, N.
    Girish, S.
    Tibbitts, J.
    Holden, S.
    Lutzker, S.
    Burris, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [49] Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
    Na Xu
    Charles H. Redfern
    Michael Gordon
    Stephen Eppler
    Bert L. Lum
    Caroline Trudeau
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1251 - 1260
  • [50] Lack of a pharmacokinetic interaction between trastuzumab and carboplatin in the presence of docetaxel: results from a phase Ib study in patients with HER2-positive metastatic or locally advanced inoperable solid tumors
    Eppler, Stephen
    Gordon, Michael S.
    Redfern, Charles H.
    Trudeau, Caroline
    Xu, Na
    Han, Kelong
    Lum, Bert L.
    ANTI-CANCER DRUGS, 2015, 26 (04) : 448 - 455
12345